Technology Transfer OfficeView Profile
Yissum - Research Development Company of the Hebrew University posted this:Naturally Occurring Compounds for Treating Pathogenic Factors Common to Cystic FibrosisCannabis project Derivatives of cannabinoids have an antimicrobial and anti biofilm effect on pseudomonas and candida which are major ethological pathogenic factors in CF Project ID : 6-2019-6720
Ivan Rodriguez Rosello posted this:
Licensing Manager at Universidad de Alicante
Montserrat Sole Castellvi posted this:
Project Manager at Knowledge Innovation Market
Consejo Superior de Investigaciones Científicas posted this:Biotechnological production of 11α hydroxylated steroids using recombinant bacteria.CSIC has developed a procedure for the biotechnological production of 11α hydroxylated steroids by generating and subsequent use of recombinant bacteria. These recombinant bacteria allow to perform microbial biotransformation processes that result in 11αhydroxylated steroid compounds from raw materials such as phytosterols and intermediate products efficiently and economically. These compounds have numerous applications in pharmacology. Companies are sought for implementing and commercializing the new technology under patent license agreement. An offer for Patent Licensing
Consejo Superior de Investigaciones Científicas posted this:Peptide for cancer control linked to IL13RR R α α 2 2 o o v v e e r r e e x x p p r r e e s s s s i i o o n n CSIC has developed a peptide capable of inhibiting the signaling of IL-13 mediated by IL13Rα2. This peptide alone or within a nanoparticle or virus-like particles can be used in a pharmaceutical composition for the treatment of pathologies in which IL13Rα2 is overexpressed. This composition would be useful in the treatment and control of metastasis of colon cancer and other tumors (i.e glioblastoma), as well as in other pathologies such as asthma, atopic dermatitis or fibrosis. Industrial partners are being sought to develop and commercialized the products through a patent licence agreement. An offer for Patent Licensing
Consejo Superior de Investigaciones Científicas posted this:Piperidine derivatives for the control of Parkinson's and Alzheimer'sCSIC has synthesized a series of piperidine derivatives that are capable of inhibiting the activity of the enzyme phosphodiesterase-8 (PDE8). This inhibitory activity makes them useful for the treatment of neurodegenerative diseases in which this enzyme is overexpressed. The compounds developed are, therefore, a new therapeutic alternative for Alzheimer's disease, and Parkinson, among others. Industrial partners from pharmaceutical industry are being sought to develop and commercialized the compounds through a patent licence agreement. An offer for Patent Licensing
Consejo Superior de Investigaciones Científicas posted this:Regulatory compounds of synaptic transmission for the treatment of neurological diseasesThe CSIC and IRYCIS (Ramón y Cajal Institute for Health Research) have developed a group of compounds. These compounds have the ability to regulate the number of synapses that are formed between neurons, as well as the probability that neurotransmitters are released from these, because they have the capability of modulate the interactions that take place between the regulatory proteins NCS-1 and Ric8a that regulate these two independent processes. Due to these neuromodulatory properties, these compounds are useful for the treatment of neurological diseases as Alzheimer's disease, Huntington or Parkinson's diseases among others. Industrial partners from the ophthalmic or pharmaceutical industry are being sought to collaborate through a patent license agreement. An offer for Patent Licensing
Consejo Superior de Investigaciones Científicas posted this:Antibiotics to treat diseases caused by HelicobacterCSIC, the University of Zaragoza, Institute Pasteur, IISA and ARAID have developed chemical derivatives that act selectively against the bacterium Helicobacter pylori, managing to reduce the bacterial load and even eradicate gastric infections caused by it. Industrial partners from the pharmaceutical industry are being sought to collaborate through a patent licence agreement. An offer for Patent Licensing
Consejo Superior de Investigaciones Científicas posted this:Molecular Method that radically improves the diagnosis of Hereditary hemorrhagic telangiectasia (HHT)Molecular Method that radically improves the diagnosis of Hereditary hemorrhagic telangiectasia (HHT). The Granada University, Health and Progress Foundation, and the CSIC have developed a diagnostic molecular system for the HHT by getting a simple liquid biopsy from the patient. Industrial partners are being sought to collaborate through a patent license agreement to use this molecular diagnostic system with the possibility of informatics support.
Nadiia Kachaput posted this:
Innovation Manager at Ukrainian Laboratories
Centre Technology Transfer CITTRU posted this:New UV-blocker for sunscreen with high bactericidal activityThe offered material is based on ZnO nanoparticles, modified with biocompatible polymer – chitosan. The material is characterized by high absorption properties of the sun’s ultraviolet (UV) radiation. Also, high antibacterial activity against resistant bacterial strains and the absence of cytotoxic activity against human skin cells of the material were confirmed. Application: cosmetics, sunscreen, skincare, medical applications
Centre Technology Transfer CITTRU posted this:A new method of the stereoselective synthesis of chosen medicinesThe subject of the offer is a new method of an asymmetric reduction of prochiral ketones and imines used in the synthesis of commonly used medicines, e.g. hormonal (eg. Cincalcet), pulmonary (eg. Salbutamol) and neurological ones (eg. Rasagiline).
Guillermo Rodríguez posted this:
R&D Manager at Biótica, Bioquímica Analítica,S.L.